Search

Background: Difficulty in modulating multisensory input, specifically the sensory over-responsive (SOR) type, is linked to pain hypersensitivity and anxiety, impacting daily function and quality of life in children and adults. Reduced cortical activity recorded under resting state has been reported, suggestive of neuromodulation as a potential therapeutic modality. This feasibility study aimed to explore neurofeedback intervention in SOR. Methods: Healthy women with SOR (n = 10) underwent an experimental feasibility study comprising four measurement time points (T1—baseline; T2—preintervention; T3—postintervention; T4—follow-up). Outcome measures included resting-state EEG recording, in addition to behavioral assessments of life satisfaction, attaining functional goals, pain sensitivity, and anxiety. Intervention targeted the upregulation of alpha oscillatory power over ten sessions. Results: No changes were detected in all measures between T1 and T2. Exploring the changes in brain activity between T2 and T4 revealed power enhancement in delta, theta, beta, and gamma oscillatory bands, detected in the frontal region (p = 0.03&ndash

Objective The purpose of this study is to explore the possibility of developing a biomarker that can discriminate early-stage Parkinson’s disease from healthy brain function using electroencephalography (EEG) event-related potentials (ERPs) in combination with Brain Network Analytics (BNA) technology and machine learning (ML) algorithms. Background Currently, diagnosis of PD depends mainly on motor signs and symptoms. However, there is need for biomarkers that detect PD at an earlier stage to allow intervention and monitoring of potential disease-modifying therapies. Cognitive impairment may appear before motor symptoms, and it tends to worsen with disease progression. While ERPs obtained during cognitive tasks performance represent processing stages of cognitive brain functions, they have not yet been established as sensitive or specific markers for early-stage PD. Methods Nineteen PD patients (disease duration of ≤2 years) and 30 healthy controls (HC) underwent EEG recording while performing visual Go/No-Go and auditory Oddball cognitive tasks. ERPs were analyzed by the BNA technology, and a ML algorithm identified a combination of features that distinguish early PD from HC. We used a logistic regression classifier with a 10-fold cross-validation. Results The ML algorithm identified a neuromarker comprising 15 BNA features that discriminated early PD patients from HC. The area-under-the-curve of the receiver-operating characteristic curve was 0.79. Sensitivity and specificity were 0.74 and 0.73, respectively. The five most important features could be classified into three cognitive functions: early sensory processing (P50 amplitude, N100 latency), filtering of information (P200 amplitude and topographic similarity), and response-locked activity (P-200 topographic similarity preceding the motor response in the visual Go/No-Go task). Conclusions This pilot study found that BNA can identify patients with early PD using an advanced analysis of ERPs. These results need to be validated in a larger PD patient sample and assessed for people with premotor phase of PD.

Background: Digital technologies have the potential to provide objective and precise tools to detect depression-related symptoms. Deployment of digital technologies in clinical research can enable collection of large volumes of clinically relevant data that may not be captured using conventional psychometric questionnaires and patient-reported outcomes. Rigorous methodology studies to develop novel digital endpoints in depression are warranted.Objective: We conducted an exploratory, cross-sectional study to evaluate several digital technologies in subjects with major depressive disorder (MDD) and persistent depressive disorder (PDD), and healthy controls. The study aimed at assessing utility and accuracy of the digital technologies as potential diagnostic tools for unipolar depression, as well as correlating digital biomarkers to clinically validated psychometric questionnaires in depression.Methods: A cross-sectional, non-interventional study of 20 participants with unipolar depression (MDD and PDD/dysthymia) and 20 healthy controls was conducted at the Centre for Human Drug Research (CHDR), the Netherlands. Eligible participants attended three in-clinic visits (days 1, 7, and 14), at which they underwent a series of assessments, including conventional clinical psychometric questionnaires and digital technologies. Between the visits, there was at-home collection of data through mobile applications. In all, seven digital technologies were evaluated in this study. Three technologies were administered via mobile applications: an interactive tool for the self-assessment of mood, and a cognitive test; a passive behavioral monitor to assess social interactions and global mobility; and a platform to perform voice recordings and obtain vocal biomarkers. Four technologies were evaluated in the clinic: a neuropsychological test battery; an eye motor tracking system; a standard high-density electroencephalogram (EEG)-based technology to analyze the brain network activity during cognitive testing; and a task quantifying bias in emotion perception.Results: Our data analysis was organized by technology – to better understand individual features of various technologies. In many cases, we obtained simple, parsimonious models that have reasonably high diagnostic accuracy and potential to predict standard clinical outcome in depression.Conclusion: This study generated many useful insights for future methodology studies of digital technologies and proof-of-concept clinical trials in depression and possibly other indications.

Electroencephalography (EEG)-based neurofeedback (NF) is a safe, non-invasive, non-painful method for treating various conditions. Current NF systems enable the selection of only one NF parameter, so that two parameters cannot be feedback simultaneously. Consequently, the ability to individually-tailor the treatment to a patient is limited, and treatment efficiency may therefore be compromised. We aimed to design, implement and test an all-in-one, novel, computerized platform for closed-loop NF treatment, based on principles from learning theories. Our prototype performs numeric evaluation based on quantifying resting EEG and event-related EEG responses to various sensory stimuli. The NF treatment was designed according to principles of efficient learning, and implemented as a gradual, patient-adaptive 1D or 2D computer game, that utilizes automatic EEG feature extraction. Verification was performed as we compared the mean area under curve (AUC) of the theta band of a dozen subjects staring at a wall or performing the NF. Most of the subjects (75%) increased their theta band AUC during the NF session compared with the trial staring at the wall (p = 0.041). Our system enables multiple feature selection and its machine learning capabilities allow an accurate discovery of patient-specific biomarkers and treatment targets. Its novel characteristics may allow for improved evaluation of patients and treatment outcomes.

Existing research has postulated a relationship between cognition and quality of life (QoL). Components of QoL such as satisfaction with social support may be particularly influential in memory for those with comorbidities. Additional research is needed to characterize the relationship between memory and QoL domains. Findings are presented from a clinical trial using BNA memory scores to assess brain health. BNA uses EEG technology and machine learning to map networks of brain functioning including working memory. Participants were older adults living in The Villages, an active lifestyle community in Florida, between the ages of 55-85, from 8/30/2017-3/11/2019. Participants were stratified into 2 groups: healthy (no CNS/psychiatric conditions; n=158) and multi-morbid (>1 CNS and/or psychiatric conditions; n=106) and compared across memory and QoL indicators. Subjective QoL was measured by the WHOQOL-BREF across 4 domains (physical, psychological, social, environmental). Scores on QoL domains were divided into 3 levels (high-medium-low) and tested for their relationship to BNA memory scores using ANOVA. Results indicate a relationship between health status, subjective QoL and BNA memory scores. Healthy subjects who scored high in the psychological QoL domain had significantly higher memory scores [F(2,152)=4.30,p=.02)]. In healthy subjects, satisfaction with social support (p=.001) had the strongest impact on memory for social QoL, while body image (p=.06) and concentration (p=.06) were the most salient predictors of psychological QoL and approached significance. Multi-morbid subjects who indicated high social ratings had higher memory scores (F(2,100)=3.75,p=.03) which relied heavily on satisfaction with social support (p=.003). Implications for policy and practice are discussed.

15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We assessed the ability of the EEG analysis algorithm Brain Network Analysis (BNA) to measure cognitive function in 15q13.3 deletion patients, and to differentiate between patient and control groups. EEG data was collected from 10 individuals with 15q13.3 microdeletion syndrome (14–18 years of age), as well as 30 age-matched healthy controls, as the subjects responded to Auditory Oddball (AOB) and Go/NoGo cognitive tasks. It was determined that BNA can be used to evaluate cognitive function in 15q13.3 microdeletion patients. This analysis also significantly differentiates between patient and control groups using 5 scores, all of which are produced from ERP peaks related to late cortical components that represent higher cognitive functions of attention allocation and response inhibition (P < 0.05).